Discovering the FORCETM Platform: Leveraging Potential to Deliver a Transformative Antibody- Oligonucleotide Conjugate Therapy for DM1 (Myotonic Dystrophy Type 1)
Time: 10:30 am
day: Pre-Conference Day Track 1
Details:
- Uncovering pre-clinical proof-of-concept with the FORCE platform in mouse models of myotonic dystrophy type 1
- Outlining the pharmacology of the FORCE platform in non human primates
- Overcoming challenges of targeted delivery to the central nervous system with the FORCE platform
